<SEC-DOCUMENT>0001213900-24-092519.txt : 20241031
<SEC-HEADER>0001213900-24-092519.hdr.sgml : 20241031
<ACCEPTANCE-DATETIME>20241031084812
ACCESSION NUMBER:		0001213900-24-092519
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241031
FILED AS OF DATE:		20241031
DATE AS OF CHANGE:		20241031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTERITY THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001131343
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-49843
		FILM NUMBER:		241412630

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000
		BUSINESS PHONE:		61 3 9349 4906

	MAIL ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRANA BIOTECHNOLOGY LTD
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0219341-6k_alterity.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
6-K</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF FOREIGN PRIVATE ISSUER</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO RULE 13a-16 OR 15d-163</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the month of    October 2024</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alterity
Therapeutics Limited</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Office)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm">333-251073</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm">333-248980</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm">333-228671</a>) and our
Registration Statements on Form F-3 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm">333-274816</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm">333-251647</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm">333-231417</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm">333-250076</a>)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 2pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALTERITY
THERAPEUTICS LIMITED</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a
development stage enterprise)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are submitted:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font-style: normal; vertical-align: top; text-align: justify; background-color: rgb(204,238,255); font-weight: normal">
<td style="font-style: normal; width: 9%; text-align: left; font-weight: normal">99.1</td>
    <td style="font-style: normal; width: 1%; font-weight: normal"><b>&nbsp;</b></td><td style="font-style: normal; text-align: justify; width: 90%; font-weight: normal"><A HREF="ea021934101ex99-1_alterity.htm">Appendix 4C &ndash; Q1 FY25 Quarterly Cash Flow Report</A></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>SIGNATURE</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Alterity Therapeutics Limited</b></font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 4%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 36%">&nbsp;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">/s/ Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Chairman</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-transform: none; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
October 31, 2024</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif">&nbsp;</div></div><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021934101ex99-1_alterity.htm
<DESCRIPTION>APPENDIX 4C - Q1 FY25 QUARTERLY CASH FLOW REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Appendix 4C &ndash; Q1 FY25 Quarterly
Cash Flow Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Highlights</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial
on track for release in January 2025</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Positive interim data reported from ATH434-202 Phase 2 clinical trial showing
the potential for ATH434 to modify disease progression in Multiple System Atrophy</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Multiple
                                            data presentations at the International Congress of Parkinson&rsquo;s Disease and Movement
                                            Disorders<SUP>&reg;</SUP> (MDS)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-size: 10pt">Appointed Abby Macnish Niven as Chief Financial Officer</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"></FONT>&#9679;</TD><TD><FONT STYLE="font-size: 10pt">Cash balance on 30 September 2024 of A$9.28m</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>MELBOURNE, AUSTRALIA AND SAN FRANCISCO,
USA &ndash; 31 October 2024:</B> Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (&ldquo;Alterity&rdquo; or &ldquo;the Company&rdquo;),
a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix
4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2024 (Q1 FY25).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;We are excited about what
this fiscal year has to offer as we started by reporting promising data from our Phase 2 clinical trial in participants with advanced
multiple system atrophy (MSA),&rdquo; said, David Stamler, M.D., Chief Executive Officer of Alterity. &ldquo;The interim results from
the ATH434-202 study suggest that ATH434 has potential to modify disease progression. Importantly, the stabilization of iron content in
certain brain regions, combined with key biomarker data, indicates that ATH434 may slow neurodegeneration by modulating brain iron levels
and reducing oxidative injury. These early data are an exciting indicator of what we might expect to see from our ATH434-201 trial in
MSA patients with early-stage disease that is expected to read out in January 2025.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;Last month, we delivered
multiple presentations at the International Congress of Parkinson&rsquo;s Disease and Movement Disorders<SUP>&reg;</SUP> (MDS), a prominent
neurology meeting. At this event, we presented clinical and preclinical data demonstrating the potential of ATH434 in a variety of neurological
conditions including early-stage MSA, advanced MSA, and Parkinson&rsquo;s disease. We look forward to presenting additional data at medical
meetings, and the topline results from both our ATH434-201 and ATH434-202 trials in calendar year 2025,&rdquo; added, Dr. Stamler.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Alterity&rsquo;s cash position
on 30 September 2024 was A$9.28 with operating cash outflows for the quarter of A$3.31M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with ASX Listing Rule
4.7C, payments of A$94k made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors&rsquo;
fees, consulting fees, remuneration and superannuation at commercial rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Operational Activities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>ATH434&ndash;202: Open-label, Biomarker Phase 2 Clinical
Trial in Advanced MSA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On 17 July 2024, Alterity
reported positive interim data from the ATH434-202 trial in participants with advanced MSA. The data were also presented in September
2024 as both a late-breaking oral presentation and poster session by Daniel O. Claassen, M.D., M.S., Professor of Neurology, Vanderbilt
University Medical Center at the International Congress of Parkinson&rsquo;s Disease and Movement Disorders<SUP>&reg;</SUP> (MDS). The
early outcomes reported from the interim analysis suggest that ATH434 has potential to modify disease progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The interim analysis included clinical
and biomarker data on 7 participants treated with ATH434 for 6 months and neuroimaging data on 3 participants who were treated for 12
months. ATH434 was well tolerated with no drug-related serious adverse events, and most adverse events were mild to moderate, showing
a favorable safety profile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The data suggest that ATH434 may
have a disease-modifying effect in MSA, as 30% of participants had stable or improved clinical outcomes (clinical responders). The average
change in Unified MSA Rating Scale Part I (UMSARS I) scores over 6 months was smaller than observed in a historical group of untreated
MSA patients, suggesting reduced disability on activities of daily living.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">At 6 months all participants exhibited
brain volume declines consistent with MSA progression; however, the clinical responders maintained stable brain volumes at 12 months.
Importantly, the clinical responders on average showed stability in iron levels on MRI in the substantia nigra, putamen and globus pallidus,
as well as stable levels of Neurofilament light chain (NfL), a marker of axonal injury, when compared to participants who declined. The
stabilization of iron content in these subcortical brain regions, combined with NfL biomarker data, indicates that ATH434 may slow neurodegeneration
by modulating brain iron levels and reducing oxidative injury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The trial remains ongoing with Topline 12-month
results expected in the first half of calendar year 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>ATH434&ndash;201: Randomized, Double-Blind Phase 2 Clinical
Trial in Early-State MSA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In September 2024, Dr.
Stamler delivered an Oral Platform presentation and poster session at MDS, entitled, &ldquo;A Phase 2 Study of ATH434, a Novel
Inhibitor of &alpha;-Synuclein Aggregation, for the Treatment of Multiple System Atrophy&rdquo;. The oral presentation and poster
described the baseline characteristics for the 77 participants from Alterity&rsquo;s ATH434-201 randomized, double-blind Phase 2
clinical trial, with a focus on baseline fluid biomarkers, neuroimaging and clinical data. The participants met strict selection
criteria designed to confirm they had early-stage (clinically probable) MSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The presentation further demonstrated
that increased iron levels were evident in multiple subcortical brain regions, with increases being observed in the substantia nigra in
nearly all subjects, and that ATH434 has potential to slow neurodegeneration based on its ability to redistribute this excess brain iron.
Data were also presented indicating that plasma levels of neurofilament light chain, a marker of neuronal injury, were correlated with
disease severity at baseline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The trial remains on track to complete
in November 2024. The data from the trial will then be analyzed and the Company expects to report topline results in January 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>bioMUSE Natural History Study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company&rsquo;s &ldquo;Biomarkers
of progression in Multiple System Atrophy&rdquo; (bioMUSE) natural history study continues to produce promising data to track the progression
of individuals with MSA and characterize MSA in terms of various biomarkers. At the MDS meeting in September 2024, a poster featuring
bioMUSE data was presented entitled, &ldquo;Association Between Clinical Progression in Multiple System Atrophy and Brain Volume Changes
Evaluated via Deep Learning Segmentation&rdquo;. The poster described the novel MRI imaging techniques and deep learning segmentation
that were used to assess brain volume in MSA brain regions of interest (ROI) in bioMUSE participants. Structural MRI plays a critical
role in both diagnosing MSA and monitoring disease progression. Subcortical brain volume shows potential as a biomarker for evaluating
disease-modifying therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Over the course of one year, MRI
with deep-learning segmentation revealed significant brain volume reduction in MSA ROIs whereas Parkinson&rsquo;s disease patients showed
no significant brain volume changes. In contrast, the MSA patients exhibited significant volume reductions in the cerebellum, globus pallidus,
and brainstem. In addition, patients with the parkinsonian variant of MSA showed significant volume loss in the putamen. The results illustrate
the correlation between the brain volume reduction and worsening clinical scores, as measured by the UMSARS, providing the basis for subcortical
brain volume as a potential biomarker in treatment studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>ATH434 for the Treatment of Parkinson&rsquo;s
Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In September 2024, a
poster was presented at MDS entitled, &ldquo;Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in
Hemiparkinsonian Macaques&rdquo;. The presentation demonstrated that ATH434 treatment led to lower iron levels in the affected area
of the brain, the substantia nigra, and improved motor performance and general function in monkeys with experimentally induced
Parkinson&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">At week 12, all 5 ATH434-treated
macaques had stable or improving scores from Baseline while two of three vehicle-treated macaques did not demonstrate improvement. The
improved general behavior was well-correlated with reduced motor impairment. These favorable parkinsonian outcomes observed in each of
the ATH434-treated monkeys were also associated with increased levels of striatal synaptophysin, a protein marker that reflects functional
connections between neurons, suggesting functional recovery of nerve endings in this critical motor pathway. These results support further
investigation of ATH434 for the treatment of Parkinson&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Corporate Activities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On September 30, 2024, Alterity
announced Abby Macnish Niven as the Company&rsquo;s Chief Financial Officer. Ms Macnish Niven consults for a range of listed and unlisted
companies in governance, finance and corporate structure. She holds Bachelor of Commerce and Bachelor of Science degrees from University
of Western Australia and is a Chartered Finance Analyst.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During the quarter, management
participated in multiple investor activities including a webinar hosted by MST Financial, and a presentation hosted by ShareCafe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">About Alterity Therapeutics Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Alterity Therapeutics is a clinical
stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company&rsquo;s
lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical
trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat
the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For
further information please visit the Company&rsquo;s web site at www.alteritytherapeutics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Authorisation &amp; Additional information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Investor and Media Contacts:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Australia</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Ana Luiza Harrop</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">we-aualteritytherapeutics@we-worldwide.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">+61 452 510 255</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">U.S.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Remy Bernarda <BR>
remy.bernarda@iradvisory.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">+1 (415) 203-6386</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Forward Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.
The Company has tried to identify such forward-looking statements by use of such words as &ldquo;expects,&rdquo; &ldquo;intends,&rdquo;
&ldquo;hopes,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;evidences&rdquo;
and &ldquo;estimates,&rdquo; and other similar expressions, but these words are not the exclusive means of identifying such statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>Important factors that could
cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled
&ldquo;Risk Factors&rdquo; in the Company&rsquo;s filings with the SEC, including its most recent Annual Report on Form 20-F as well as
reports on Form 6-K, including, but not limited to the following: statements relating to the Company&rsquo;s drug development program,
including, but not limited to the initiation, progress and outcomes of clinical trials of the Company&rsquo;s drug development program,
including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing,
regulatory approval, production and marketing of the Company&rsquo;s drug components, including, but not limited to, ATH434, the ability
of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of
the Company&rsquo;s drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty
of obtaining patent protection for the Company&rsquo;s intellectual property or trade secrets, the uncertainty of successfully enforcing
the Company&rsquo;s patent rights and the uncertainty of the Company freedom to operate.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>Any forward-looking statement
made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is
made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><I>Rule 4.7B</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Appendix 4C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Quarterly cash flow report
for entities subject to Listing Rule 4.7B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: black 1pt solid; width: 100%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of entity</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; font-size: 10pt; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alterity Therapeutics Limited</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; width: 33%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABN</B></FONT></TD>
    <TD STYLE="padding: 3pt; width: 34%">&nbsp;</TD>
    <TD STYLE="padding: 3pt; width: 33%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Quarter ended (&ldquo;current quarter&rdquo;)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37 080 699 065</FONT></TD>
    <TD STYLE="padding: 3pt; border-right: black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 3pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30 September 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; vertical-align: top">Consolidated statement of cash flows</TD><TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Current quarter $A&rsquo;000</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year to date (3 months) $A&rsquo;000</TD><TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left; font-weight: bold">1.</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">Cash flows from operating activities</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; width: 5%; text-align: left">1.1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: left">Receipts from customers</TD><TD STYLE="border-right: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; width: 1%; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">1.2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Payments for</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(a)&nbsp;&nbsp;&nbsp;research and development</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,994</TD><TD STYLE="text-align: left">)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,994</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>)</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(b)&nbsp;&nbsp;&nbsp;product manufacturing and operating costs</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(c)&nbsp;&nbsp;&nbsp;advertising and marketing</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(88</TD><TD STYLE="text-align: left">)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(88</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>)</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(d)&nbsp;&nbsp;&nbsp;leased assets</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(e)&nbsp;&nbsp;&nbsp;staff costs</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(789</TD><TD STYLE="text-align: left">)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(789</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>)</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(f)&nbsp;&nbsp;&nbsp;&nbsp;administration and corporate costs</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(507</TD><TD STYLE="text-align: left">)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(507</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>)</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">1.3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Dividends received (see note 3)</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">1.4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Interest received</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">1.5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Interest and other costs of finance paid</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">1.6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Income taxes paid</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">1.7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Government grants and tax incentives</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; padding-bottom: 1.5pt; text-align: left">1.8</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Other (provide details if material)</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-bottom: 1.5pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: left">1.9</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Net cash from / (used in) operating activities</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,305</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">)</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,305</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; font-weight: bold; text-align: left"><B>)</B></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-weight: bold; width: 5%">2.</TD><TD STYLE="border-top: Black 1pt solid; font-weight: bold; width: 1%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font-weight: bold; text-align: left; width: 71%">Cash flows from investing activities</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: right; width: 9%">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; text-align: right; width: 9%">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">2.1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Payments to acquire or for:</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(a)&nbsp;&nbsp;&nbsp;entities</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(b)&nbsp;&nbsp;&nbsp;businesses</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(c)&nbsp;&nbsp;&nbsp;property, plant and equipment</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(d)&nbsp;&nbsp;&nbsp;investments</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(e)&nbsp;&nbsp;&nbsp;intellectual property</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(f)&nbsp;&nbsp;&nbsp;other non-current assets</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="border-top: Black 1.5pt solid; width: 85%">ASX Listing Rules Appendix 4C (17/07/20)<BR> + See chapter 19 of the ASX Listing Rules for defined terms.</TD><TD STYLE="border-top: Black 1.5pt solid; text-align: right; width: 15%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><B>Appendix 4C</B></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><B>Quarterly cash flow report for entities subject to Listing Rule&nbsp;4.7B</B></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-left: 2pt; text-align: left; border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; vertical-align: top">Consolidated statement of cash flows</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Current quarter</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$A&rsquo;000</B></P></TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Year to date (3 months)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$A&rsquo;000</B></P></TD><TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; width: 5%; text-align: left">2.2</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: left">Proceeds from disposal of:</TD><TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(a)&nbsp;&nbsp;&nbsp;entities</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(b)&nbsp;&nbsp;&nbsp;businesses</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(c)&nbsp;&nbsp;&nbsp;property, plant and equipment</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(d)&nbsp;&nbsp;&nbsp;investments</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(e)&nbsp;&nbsp;&nbsp;intellectual property</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(f)&nbsp;&nbsp;&nbsp;other non-current assets</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">2.3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Cash flows from loans to other entities</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">2.4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Dividends received (see note 3)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; padding-bottom: 1pt; text-align: left">2.5</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">Other (provide details if material)</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: left">2.6</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Net cash from / (used in) investing activities</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-weight: bold; width: 5%">3.</TD><TD STYLE="border-top: Black 1pt solid; font-weight: bold; width: 1%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font-weight: bold; text-align: left; width: 70%">Cash flows from financing activities</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; text-align: right; width: 9%">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; text-align: right; width: 9%">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">3.1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Proceeds from issues of equity securities (excluding convertible debt securities)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">3.2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Proceeds from issue of convertible debt securities</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">3.3</TD><TD>&nbsp;</TD>
    <TD>Proceeds from exercise of options</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">3.4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Transaction costs related to issues of equity securities or convertible debt securities</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31</TD><TD STYLE="text-align: left">)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">3.5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Proceeds from borrowings</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">3.6</TD><TD>&nbsp;</TD>
    <TD>Repayment of borrowings</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">3.7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Transaction costs related to loans and borrowings</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">3.8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Dividends paid</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid; padding-left: 2pt; text-align: left">3.9</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">Other (provide details if material)</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: left">3.10</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Net cash from / (used in) financing activities</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(71</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">)</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(71</TD><TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 251pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 251pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="border-top: Black 1.5pt solid; width: 85%">ASX Listing Rules Appendix 4C (17/07/20)<BR> + See chapter 19 of the ASX Listing Rules for defined terms.</TD><TD STYLE="border-top: Black 1.5pt solid; text-align: right; width: 15%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><B>Appendix 4C</B></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><B>Quarterly cash flow report for entities subject to Listing Rule&nbsp;4.7B</B></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 251pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 2pt; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-weight: bold">4.</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font-weight: bold">Net increase / (decrease) in cash and cash equivalents for the period</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; width: 5%; text-align: left">4.1</TD><TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: left">Cash and cash equivalents at beginning of period</TD><TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,639</TD><TD STYLE="border-right: Black 1pt solid; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">4.2</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">Net cash from / (used in) operating activities (item 1.9 above)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,305</TD><TD STYLE="text-align: left">)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,305</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">4.3</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">Net cash from / (used in) investing activities (item 2.6 above)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">4.4</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">Net cash from / (used in) financing activities (item 3.10 above)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71</TD><TD STYLE="text-align: left">)</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid; padding-left: 2pt; text-align: left"><B>4.5</B></TD><TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">Effect of movement in exchange rates on cash held</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><B>20</B></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><B>20</B></TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: left">4.6</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Cash and cash equivalents at end of period</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">9,283</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">9,283</TD><TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 2pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; font-weight: bold; text-align: left">5.</TD><TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; border-top: Black 1pt solid; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Reconciliation of cash and cash equivalents</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts</P></TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Current quarter</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$A&rsquo;000</B></P></TD><TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Previous quarter</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$A&rsquo;000</B></P></TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; width: 5%; text-align: left">5.1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: left">Bank balances</TD><TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9,283</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,639</TD><TD STYLE="border-right: Black 1pt solid; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">5.2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Call deposits</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">5.3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Bank overdrafts</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid; padding-left: 2pt; text-align: left">5.4</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">Other (provide details)</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-align: left">5.5</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Cash and cash equivalents at end of quarter (should equal item 4.6 above)</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">9,283</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">12,639</TD><TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 2pt; border-top: Black 1pt solid; font-weight: bold; text-align: left">6.</TD><TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; border-top: Black 1pt solid; font-weight: bold; vertical-align: top">Payments to related parties of the entity and their associates</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Current quarter</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$A&rsquo;000</B></P></TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; padding-bottom: 1pt; width: 5%; text-align: left">6.1</TD><TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 82%; text-align: left">Aggregate amount of payments to related parties and their associates included in item 1</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right">94</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid; padding-left: 2pt; padding-bottom: 1pt; text-align: left">6.2</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">Aggregate amount of payments to related parties and their associates included in item 2</TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="7" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 2pt; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt"><I>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt; border: Black 1pt solid; width: 100%">The amount at 6.1 includes payment of director&rsquo;s fees and salaries and consulting fees, excluding GST where applicable.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="border-top: Black 1.5pt solid; width: 85%">ASX Listing Rules Appendix 4C (17/07/20)<BR> + See chapter 19 of the ASX Listing Rules for defined terms.</TD><TD STYLE="border-top: Black 1.5pt solid; text-align: right; width: 15%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><B>Appendix 4C</B></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><B>Quarterly cash flow report for entities subject to Listing Rule&nbsp;4.7B</B></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 2pt; vertical-align: top; text-align: left; font-weight: bold">7.</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: left; border-bottom: Black 1pt solid; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Financing facilities</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Note: the term &ldquo;facility&rsquo; includes all forms of financing arrangements available to the entity.</I></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Add notes as necessary for an understanding of the sources of finance available to the entity.</I></P></TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Total facility<BR>
 amount at quarter end</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$A&rsquo;000</B></P></TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Amount drawn at<BR>
 quarter end</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$A&rsquo;000</B></P></TD><TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid; padding-left: 2pt; width: 5%; text-align: left">7.1</TD><TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 70%; text-align: left">Loan facilities</TD><TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid; padding-left: 2pt; text-align: left">7.2</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">Credit standby arrangements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid; padding-left: 2pt; text-align: left">7.3</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">Other (please specify)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid; padding-left: 2pt; text-align: left">7.4</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">Total financing facilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="11"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid; padding-left: 2pt; text-align: left">7.5</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">Unused financing facilities available at quarter end</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-left: 2pt; border-left: Black 1pt solid; text-align: left">7.6</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-left: 2pt; text-align: left; font-weight: bold">8.</TD><TD STYLE="border-top: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font-weight: bold">Estimated cash available for future operating activities</TD><TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; border-top: Black 1pt solid; text-align: center; font-weight: bold">$A&rsquo;000</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-top: Black 1pt solid; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid; padding-left: 2pt; width: 5%; text-align: left">8.1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 82%; text-align: left">Net cash from / (used in) operating activities (item 1.9)</TD><TD STYLE="border-left: Black 1pt solid; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(3,305</TD><TD STYLE="border-right: Black 1pt solid; width: 1%; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid; padding-left: 2pt; text-align: left">8.2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Cash and cash equivalents at quarter end (item 4.6)</TD><TD STYLE="border-left: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">9,283</TD><TD STYLE="border-right: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid; padding-left: 2pt; text-align: left">8.3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Unused finance facilities available at quarter end (item 7.5)</TD><TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid; padding-left: 2pt; text-align: left">8.4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Total available funding (item 8.2 + item 8.3)</TD><TD STYLE="border-left: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">9,283</TD><TD STYLE="border-right: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="7"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 2pt; text-align: left">8.5</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Estimated quarters of funding available (item 8.4 divided by item 8.1)</TD><TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2.8</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-right: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0pt 0pt 0pt 0.6in"><I>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as &ldquo;N/A&rdquo;. Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</I>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt">8.6</TD>
    <TD COLSPAN="2" STYLE="padding-left: 2pt"><FONT STYLE="font-size: 10pt">If item 8.5 is less than 2 quarters, please provide answers to the following questions:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt; width: 6%">&nbsp;</TD>
    <TD STYLE="padding-left: 2pt; width: 7%">8.6.1</TD>
  <TD STYLE="width: 87%">Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 2pt; border-top: Black 1pt solid; border-left: Black 1pt solid">Answer:</TD>
  <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid">N/A</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 2pt">8.6.2</TD>
  <TD>Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 2pt; border-top: Black 1pt solid; border-left: Black 1pt solid">Answer:</TD>
  <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid">N/A</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 2pt">8.6.3</TD>
  <TD>Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 2pt; border-top: Black 1pt solid; border-left: Black 1pt solid">Answer:</TD>
  <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid">N/A</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="padding-left: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0.6in"><FONT STYLE="font-size: 10pt"><I>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</I></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="border-top: Black 1.5pt solid; width: 85%">ASX Listing Rules Appendix 4C (17/07/20)<BR> + See chapter 19 of the ASX Listing Rules for defined terms.</TD><TD STYLE="border-top: Black 1.5pt solid; text-align: right; width: 15%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><B>Appendix 4C</B></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><B>Quarterly cash flow report for entities subject to Listing Rule&nbsp;4.7B</B></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Compliance statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="text-align: left">This statement has been prepared in accordance with accounting standards and policies which comply with
Listing Rule 19.11A.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD><TD>This statement gives a true and fair view of the matters disclosed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 13%">Date:</TD>
  <TD STYLE="width: 87%">31 October 2024</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Authorised by:</TD>
  <TD>David Stamler, CEO</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>(Name of body or officer authorising release &ndash; see
note 4)</TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="text-align: justify">This quarterly cash flow report and the accompanying activity report provide a
basis for informing the market about the entity&rsquo;s activities for the past quarter, how they have been financed and the effect this
has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing
Rules is encouraged to do so.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD STYLE="text-align: justify">If this quarterly cash flow report has been prepared in accordance with Australian
Accounting Standards, the definitions in, and provisions of, <I>AASB 107: Statement of Cash Flows </I>apply to this report. If this quarterly
cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding
equivalent standard applies to this report.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD STYLE="text-align: justify">Dividends received may be classified either as cash flows from operating activities
or cash flows from investing activities, depending on the accounting policy of the entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD STYLE="text-align: justify">If this report has been authorised for release to the market by your board of
directors, you can insert here: &ldquo;By the board&rdquo;. If it has been authorised for release to the market by a committee of your
board of directors, you can insert here: &ldquo;By the [<I>name of board committee </I>&ndash; <I>eg Audit and Risk Committee</I>]&rdquo;.
If it has been authorised for release to the market by a disclosure committee, you can insert here: &ldquo;By the Disclosure Committee&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 28.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD><TD STYLE="text-align: justify">If this report has been authorised for release to the market by your board of directors
and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council&rsquo;s <I>Corporate Governance
Principles and Recommendations</I>, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true
and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management
and internal control which is operating effectively.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="border-top: Black 1.5pt solid; width: 85%">ASX Listing Rules Appendix 4C (17/07/20)<BR> + See chapter 19 of the ASX Listing Rules for defined terms.</TD><TD STYLE="border-top: Black 1.5pt solid; text-align: right; width: 15%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V -L# 2(  A$! Q$!_\0
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MN+3C)6T:L3":FFXWT;6JMJOTUW"BOXC?^"]G[?\ ^VC^S?\ \%7_ -G/X,_
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MAN;2:1GCM8E_%7P99VE]_P '=EU!>V\-S"O[5_C^\2*9%D47.G? OQ+J6GW
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+5VDWJD[7M9(/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
